Eli Lilly & vs Astrazeneca: Fair Value & Quality
Both stocks run through our 21 valuation models. Here is how Eli Lilly & (LLY) and Astrazeneca (AZN) compare, as of Jul 23, 2026.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Eli Lilly & · Health Care
Astrazeneca · Health Care
Bottom line
As of Jul 23, 2026, Fair Value Calculator sees Astrazeneca as the more attractively valued of the two: Eli Lilly & trades at $1,175 versus a fair value of $397 (-66%), while Astrazeneca trades at $169 versus $130 (-24%).
Eli Lilly & has the higher quality score (74/100).
See the full analysis →See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models, not a recommendation and not financial advice. Values change with price and fundamentals; the date shown above applies.